Eli Lilly and Company
Coverage of Eli Lilly and Company in the Nexus archive.
- CVS to restore coverage of Zepbound, add Eli Lilly's obesity pill to drug plans
CVS Health will add Zepbound coverage starting October 1 and begin covering Eli Lilly's newly approved obesity treatment, Foundayo, on June 1. The moves expand drug plan accessibility for weight management medications.
- Lilly Goes on $20B Buying Spree as It Seeks Next Act
Lilly is investing $20 billion in acquisitions to fuel its next strategic growth phase, signaling confidence in future opportunities.
- Lilly to Buy Three Vaccine Developers for Up to $3.8 Billion
Eli Lilly and Company is acquiring three vaccine developers for up to $3.8 billion. The transaction highlights the company's expansion into vaccine development and biotechnology innovation.
- Lilly’s One-Time Cholesterol Shot
Eli Lilly and Company has developed a one-time cholesterol shot, offering a potential breakthrough in managing high cholesterol with a single treatment.
- AutoZone & Ferrari Slide; Eli Lilly Announces Acquisitions | Stock Movers
AutoZone and Ferrari stocks declined, while Eli Lilly announced acquisitions, impacting stock market movers. The article highlights mixed performance in the automotive and pharmaceutical sectors.
- Lilly’s new experimental shot produced 28% weight loss
Eli Lilly has developed an experimental weight loss injection that achieved 28% weight loss in trials. The new shot differs from existing medications Zepbound and Foundayo by combining three active components: GIP, GLP-1, and glucagon.